Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 43
Filter
2.
Arq. ciências saúde UNIPAR ; 24(1): 35-39, jan-abr. 2020.
Article in Portuguese | LILACS | ID: biblio-1095986

ABSTRACT

O câncer infanto-juvenil corresponde a um grupo de várias doenças que têm em comum a proliferação descontrolada de células anormais e que pode ocorrer em qualquer órgão em fase de desenvolvimento. Assim, o objetivo deste estudo foi descrever o perfil clínico e epidemiológico de crianças e adolescentes atendidos na UNACON durante o ano de 2017. Trata-se de um estudo descritivo, de corte transversal, desenvolvido a partir da análise de 20 prontuários de crianças e adolescentes com câncer. Foram coletados dados sobre as características sociodemográficas e clínicas-epidemiológicas dos pacientes. Os dados foram digitados, revisados e analisados no programa estatístico SPSS, na versão 21.0. Foram calculadas as frequências e a média das variáveis de interesse. Observou-se que a maioria dos pacientes tinha de um a três anos (45,0%), era do sexo masculino (60,0%), pardos (70,0%), com renda familiar de até um salário mínimo (60,0%) e metade procedia do interior do estado (50,0%), sendo o tipo de câncer mais diagnosticado a leucemia linfoide aguda (45,0%) e o principal tratamento utilizado a quimioterapia (95,0%), causando principalmente alopecia (100%), algia (100%), náuseas (65,0%), palidez (40,0%) e febre (25,0%) nos pacientes. Foi possível concluir que conhecer o perfil pode contribuir para a tomada de decisões da equipe gestora e profissionais de saúde da unidade no estabelecimento de medidas assistenciais aos pacientes, visando um atendimento mais humanizado, voltado para as necessidades sociodemográficas e levando em consideração as características clínicas-epidemiológicas desse grupo populacional.


Child and youth cancer corresponds to a group of several diseases that have in common the uncontrolled proliferation of abnormal cells and that can occur in any organ during the development phase. Thus, the purpose of this study was to describe the clinical and epidemiological profile of children and adolescents cared at UNACON during 2017. It is a descriptive, cross-sectional study developed from the analysis of 20 records of children and adolescents with cancer. Data on the sociodemographic and clinical-epidemiological characteristics of the patients were collected. The data were entered, reviewed and analyzed using the SPSS statistical program, version 21.0. The frequencies and the average of the variables of interest were calculated. It could be observed that the majority of patients were aged between one and three years (45.0%), male (60.0%), brown (70.0%), with a family income of up to one minimum wage (60.0%) and half (50.0%) came from the interior of the state, with acute lymphoid leukemia (45.0%) being the most frequent diagnosis, and chemotherapy (95.0%) the most frequent treatment used, causing mainly alopecia (100%), pain (100%), nausea (65.0%), pallor (40.0%) and fever (25.0%) in patients. It was possible to conclude that knowing the profile can contribute to the decision-making of the management team and health professionals at the health facility in the establishment of care measures for patients, aiming at a more humanized care, focused on sociodemographic needs and taking into account the clinical-epidemiological characteristics of this population group.


Subject(s)
Humans , Male , Female , Infant , Child, Preschool , Child , Health Profile , Neoplasms , Therapeutics , Leukemia/prevention & control , Medical Records , Diagnosis , Drug Therapy , Alopecia/drug therapy , Health Services Needs and Demand , Medical Oncology , Nausea/drug therapy
3.
ABCS health sci ; 44(3): 209-212, 20 dez 2019. ilus
Article in English, Portuguese | LILACS | ID: biblio-1047756

ABSTRACT

INTRODUÇÃO: O tratamento do câncer vem evoluindo a cada dia. Entretanto, efeitos adversos como alterações dermatológicas apresentam um grande impacto psicossocial ao paciente oncológico. Uma dessas alterações dermatológicas é a alopecia, caracterizada pela perda dos fios da sobrancelha e do couro cabeludo. RELATO DE CASO: Foram referidos dois casos de pacientes em tratamento quimioterápico com alopecia parcial e total. Ambas receberam tratamento por meio do Minoxidil, de uso tópico, havendo repilação completa após três meses. Não foram observados efeitos adversos. CONCLUSÃO: A loção tópica de Minoxidil mostrou-se um método efetivo e seguro para tratar a alopecia parcial e total em pacientes que ainda estão em tratamento oncológico.


INTRODUCTION: The treatment of cancer has been evolving every day. However, adverse effects such as dermatological changes have a great psychosocial impact on cancer patients. One dermatological change is alopecia, characterized by loss of eyebrow and scalp strands. CASE REPORT: Two cases of patients undergoing chemotherapy with partial and total alopecia were reported. Both were treated with Minoxidil, which was topically used, with complete repilation after three months. No adverse effects observed. CONCLUSION: Minoxidil topical lotion has proven to be an effective and safe method to treat partial and total alopecia in patients still undergoing cancer treatment.


Subject(s)
Humans , Female , Middle Aged , Aged , Dermatology , Alopecia/drug therapy , Integrative Oncology , Minoxidil/therapeutic use , Drug Therapy
4.
An. bras. dermatol ; 94(4): 416-421, July-Aug. 2019. tab, graf
Article in English | LILACS | ID: biblio-1038289

ABSTRACT

Abstract: Background: Frontal fibrosing alopecia is a condition of unknown origin, histologically similar to classic lichen planopilaris and generally observed in postmenopausal women with alopecia of the frontal-temporal hairline. Objectives: To describe the clinical, dermatoscopic, and histopathological characteristics and the treatment used in patients who have frontal fibrosing alopecia at the Alopecia Outpatient Clinic in a university hospital. Methods: Retrospective descriptive study performed by reviewing medical charts and biopsies of the scalp. Results: Sixteen patients were analyzed, all of them female, 93.75% of them postmenopausal, and 56.25% brown-skinned. All had frontal alopecia (100%), followed by temporal alopecia (87.5%) and madarosis (87.5%). On dermatoscopy, perifollicular erythema and tubular scales were found as a sign of disease activity. Of the patients, 68.75% had associated autoimmune diseases, including lupus, thyroid disease and vitiligo. Of the 13 biopsies from 8 patients, 10 showed microscopic aspects compatible with frontal fibrosing alopecia. Laboratory tests did not show major abnormalities and minoxidil was the most used treatment. Study limitation: Data collection limited by the study's retrospective design associated to flaws while filling in the medical charts and absence in standards to the collection and processing of the pathology and histopathological examination. Conclusions: A demographical, clinical, and histopathological description of 16 patients diagnosed with frontal fibrosing alopecia, which remains a challenging disease, of unknown origin, and frequently associated with autoimmune diseases. This study reinforces literary findings. However, more research is needed to establish the pathogenesis and effective treatments.


Subject(s)
Humans , Female , Adult , Middle Aged , Aged , Aged, 80 and over , Alopecia/pathology , Scalp/pathology , Biopsy , Fibrosis , Retrospective Studies , Hair Follicle/pathology , Dermoscopy/methods , Alopecia/drug therapy , Hospitals, University
7.
An. bras. dermatol ; 92(5,supl.1): 79-81, 2017. graf
Article in English | LILACS | ID: biblio-887090

ABSTRACT

Abstract Frontal fibrosing alopecia is a variant of lichen planopilaris with marginal progressive hair loss on the scalp, eyebrows and axillae. We report a case of frontal fibrosing alopecia and lichen planus pigmentosus in a postmenopausal woman, that started with alopecia on the eyebrows and then on the frontoparietal region, with periocular and cervical hyperpigmentation of difficult management. The condition was controlled with systemic corticosteroid therapy and finasteride. Lichen planus pigmentosus is an uncommon variant of lichen planus frequently associated with frontal fibrosing alopecia in darker phototipes. It should be considered in patients affected by scarring alopecia with a pattern of lichen planopilaris and areas of skin hyperpigmentation revealing perifollicular hyperpigmentation refractory to multiple treatments. This case illustrates diagnostic and therapeutic challenge in face of scarring alopecia and perifollicular hyperpigmentation.


Subject(s)
Humans , Female , Aged , Hyperpigmentation/pathology , Hyperpigmentation/drug therapy , Alopecia/pathology , Alopecia/drug therapy , Lichen Planus/drug therapy , Skin/pathology , Biopsy , Treatment Outcome , Adrenal Cortex Hormones/therapeutic use , Postmenopause , Finasteride/therapeutic use , Dermoscopy , Forehead/pathology , Lichen Planus/pathology
8.
Rev. méd. Chile ; 144(12): 1584-1590, dic. 2016.
Article in Spanish | LILACS | ID: biblio-845489

ABSTRACT

Finasteride is a 5-α reductase inhibitor that is widely used in the management of benign prostate hyperplasia and male pattern hair loss. It is well known that these agents improve the quality of life in men suffering from these conditions. However, they are associated with some transient and even permanent adverse effects. The aim of this article is to clarify the controversies about the safety of finasteride by analyzing the evidence available in the literature.


Subject(s)
Humans , Male , Finasteride/adverse effects , 5-alpha Reductase Inhibitors/adverse effects , Prostatic Hyperplasia/drug therapy , Prostatic Neoplasms/prevention & control , Spermatogenesis/drug effects , Blood Glucose/metabolism , Finasteride/therapeutic use , Alopecia/drug therapy , Lipid Metabolism/drug effects , 5-alpha Reductase Inhibitors/therapeutic use , Erectile Dysfunction/chemically induced
9.
An. bras. dermatol ; 91(1): 87-88, Jan.-Feb. 2016. graf
Article in English | LILACS | ID: lil-776434

ABSTRACT

Abstract Rare cases of hypertrichosis have been associated with topically applied minoxidil. We present the first reported case in the Brazilian literature of generalized hypertrichosis affecting a 5-year-old child, following use of minoxidil 5%, 20 drops a day, for hair loss. The laboratory investigation excluded hyperandrogenism and thyroid dysfunction. Topical minoxidil should be used with caution in children.


Subject(s)
Child , Female , Humans , Hypertrichosis/chemically induced , Minoxidil/adverse effects , Vasodilator Agents/adverse effects , Administration, Cutaneous , Alopecia/drug therapy
10.
An. bras. dermatol ; 89(6): 1003-1004, Nov-Dec/2014. graf
Article in English | LILACS | ID: lil-727627

ABSTRACT

Graham-Little-Piccardi-Lassueur Syndrome is a rare form of Lichen Planus, characterized by the presence of the triad: non-scarring hair loss in the inguinal and axillary regions and follicular spinous or disseminated acuminate papules; typical, cutaneous or mucous LP; and scarring alopecia of the scalp with or without atrophy. These features do not have to be present simultaneously.


Subject(s)
Humans , Female , Middle Aged , Scalp/pathology , Dermatitis/pathology , Lichen Planus/pathology , Scalp/drug effects , Skin/pathology , Syndrome , Treatment Outcome , Adrenal Cortex Hormones/therapeutic use , Dermatitis/drug therapy , Alopecia/pathology , Alopecia/drug therapy , Lichen Planus/drug therapy
11.
Indian J Dermatol Venereol Leprol ; 2014 Nov-Dec; 80(6): 521-525
Article in English | IMSEAR | ID: sea-154887

ABSTRACT

Background: The effectiveness of finasteride and dutasteride in women with androgenetic alopecia has been the subject of debate. Aim: To evaluate the effectiveness of finasteride and dutasteride on hair loss in women with androgenetic alopecia over a period of 3 years. Methods: From a database containing systematically retrieved data on 3500 women treated for androgenetic alopecia between 2002 and 2012 with finasteride 1.25 mg or dutasteride 0.15 mg, a random sample stratified for age and type of medication was taken to yield 30 women in two age categories: below and above 50 years, and for both medications. Hair thickness of the three thinnest hairs was measured from standardized microscopic images at three sites of the scalp at the start of the treatment and after 3 years of continuous medication intake. The macroscopic images were evaluated independently by three European dermatologists/hair experts. The diagnostic task was to identify the image displaying superior density of the hair. Results: Both age categories showed a statistically significant increase in hair thickness from baseline over the 3‑year period for finasteride and dutasteride (signed rank test, P = 0.02). Hair thickness increase was observed in 49 (81.7%) women in the finasteride group and in 50 (83.3%) women in the dutasteride group. On average, the number of post‑treatment images rated as displaying superior density was 124 (68.9%) in the finasteride group, and 118 (65.6%) in the dutasteride group. Dutasteride performed statistically significantly better than finasteride in the age category below 50 years at the central and vertex sites of the scalp. Conclusions: Finasteride 1.25 mg and dutasteride 0.15 mg given daily for 3 years effectively increased hair thickness and arrested further deterioration in women with androgenetic alopecia.


Subject(s)
Adult , Aged , Alopecia/classification , Alopecia/drug therapy , Alopecia/epidemiology , Alopecia/genetics , Androgens , Azasteroids/administration & dosage , Azasteroids/therapeutic use , Female , Finasteride/administration & dosage , Finasteride/therapeutic use , Humans , Middle Aged
12.
Journal of Medical Council of Islamic Republic of Iran. 2014; 32 (2): 161-169
in Persian | IMEMR | ID: emr-161884

ABSTRACT

Androgenetic alopecia is an extremely common disorder affecting 70% of men and 40% of women in their life. Men present with gradual thinning in the temporal areas, producing a reshaping of the anterior part of the hairline and progress to vertex balding. Women with androgenetic alopecia usually present with diffuse thinning on the crown. Only 2 drugs [minoxidil and finasteride] currently have FDA-approved indications for treatment of androgenetic alopecia. Due to the frequency and the often significant impairment of life perceived by the affected patients, diagnosis and treatment of androgenetic alopecia is particularly important. This article briefly reviews the definition, diagnosis and treatment options of androgenetic alopecia


Subject(s)
Humans , Male , Female , Alopecia/drug therapy , Minoxidil , Finasteride
13.
Rev. chil. dermatol ; 30(1): 52-61, 2014. ilus, tab
Article in Spanish | LILACS | ID: biblio-835915

ABSTRACT

La pérdida excesiva y falta de crecimiento capilar son un motivo frecuente de consulta dermatológica. En las últimas décadas, la investigación constante en la biología folicular ha permitido desarrollar numerosos productos farmacológicos que serían capaces de modificar la biología folicular y capilar, con resultados prometedores. No obstante, su indicación así como también las expectativas de éxito terapéutico deben ser tomadas con prudencia, ya que muchos de estos productos carecen de evidencia científica clínica en enfermedades capilares. En la siguiente revisión, se analizarán los mecanismos de acción y evidencia científica clínica de los principales productos capilares comercializados.


Insufficient growth and excessive hair loss are a common complaint in dermatologic consultation. In the past decades, a sustained research in hair follicle biology has prompted the development of many drugs that modify hair shaft and follicle biology, with promising results. However, their use as well as positive expectations have to be taken with caution, since many of them lack clinical evidence in hair diseases. In this paper, the mechanism of action and clinical evidence of the most common hair products available will be analyzed.


Subject(s)
Humans , Alopecia/drug therapy , Dermatologic Agents/therapeutic use , Androgen Antagonists/therapeutic use , Anti-Inflammatory Agents/therapeutic use , Antioxidants/therapeutic use , Hair Follicle/growth & development , Hair Follicle , Hair Follicle/blood supply
14.
Indian J Dermatol Venereol Leprol ; 2013 Sept-Oct; 79(5): 626-640
Article in English | IMSEAR | ID: sea-148755

ABSTRACT

Female pattern hair loss (FPHL) is a common cause of hair loss in women characterized by diffuse reduction in hair density over the crown and frontal scalp with retention of the frontal hairline. Its prevalence increases with advancing age and is associated with significant psychological morbidity. The pathophysiology of FPHL is still not completely understood and seems to be multifactorial. Although androgens have been implicated, the involvement of androgen-independent mechanisms is evident from frequent lack of clinical or biochemical markers of hyperandrogenism in affected women. The role of genetic polymorphisms involving the androgen and estrogen receptors is being increasingly recognized in its causation and predicting treatment response to anti-androgens. There are different clinical patterns and classifications of FPHL, knowledge of which facilitates patient management and research. Chronic telogen effluvium remains as the most important differential diagnosis. Thorough history, clinical examination, and evaluation are essential to confirm diagnosis. Patients with clinical signs of androgen excess require assessment of biochemical parameters and imaging studies. It is prudent to screen the patients for metabolic syndrome and cardiovascular risk factors. The treatment comprises medical and/or surgical modalities. Medical treatment should be initiated early as it effectively arrests hair loss progression rather than stimulating regrowth. Minoxidil continues to be the first line therapy whereas anti-androgens form the second line of treatment. The progressive nature of FPHL mandates long-term treatment for sustained effect. Medical therapy may be supplemented with cosmetic concealment in those desirous of greater hair density. Surgery may be worthwhile in some carefully selected patients.


Subject(s)
5-alpha Reductase Inhibitors/therapeutic use , Alopecia/diagnosis , Alopecia/drug therapy , Alopecia/genetics , Androgen Antagonists/therapeutic use , Female , Finasteride/therapeutic use , Humans , Minoxidil/therapeutic use , Vasodilator Agents/therapeutic use
15.
Indian J Dermatol Venereol Leprol ; 2013 Sept-Oct; 79(5): 613-625
Article in English | IMSEAR | ID: sea-148754

ABSTRACT

Androgenetic alopecia (AGA) is one of the commonest reasons for dermatological consultation. Over the last few years our understanding of the pathophysiology of AGA has improved and this has paved way for better diagnostic and therapeutic options. Recent research has dwelled on the role of stem cells in the pathophysiology of AGA and has also identified newer genetic basis for the condition. Dermoscopy/trichoscopy has emerged as a useful diagnostic tool for AGA. While the major treatment options continue to be topical minoxidil, systemic Finasteride and hair transplantations, newer modalities are under investigation. Specific diagnostic and treatment recommendations have also been developed on evidence based principles. This article reviews the recent concepts in relation to AGA. With regards to the pathophysiology we have tried to stress on recent knowledge of the molecular and genetic basis of AGA. We have emphasized on an evidence based approach for treatment and diagnosis.


Subject(s)
5-alpha Reductase Inhibitors/therapeutic use , Alopecia/diagnosis , Alopecia/drug therapy , Alopecia/physiopathology , Diagnosis, Differential , Female , Finasteride/therapeutic use , Humans , Male , Minoxidil/therapeutic use , Vasodilator Agents/therapeutic use
16.
Rev. chil. dermatol ; 28(4): 371-403, 2012. ilus, tab, graf
Article in Spanish | LILACS | ID: lil-774866

ABSTRACT

Como en el varón, el tratamiento tópico de alopecia de patrón femenino (AF) es con minoxidil al 3 por ciento - 5 por ciento dos veces al día. También puede usarse el minoxidil combinado con α-tocoferol o con otros tratamientos tópicos que elevan localmente el factor de crecimiento vascular endotelial. Comentamos nuestra experiencia con esta asociación. Los efectos secundarios más frecuentes en mujeres son la dermatitis de contacto y la hipertricosis de cara y antebrazos. Cuando la alopecia femenina se asocia a elevados niveles de andrógenos hay que utilizar terapéutica antiandrogénica. El síndrome de persistencia de la adrenarquía (SAHA suprarrenal) y alopecia en hiperandrogenismo suprarrenal deben tratarse con supresión suprarrenal y antiandrógenos. La supresión suprarrenal la efectuamos con glucocorticoides como dexametasona, prednisona o deflazacort. La terapia antiandrogénica incluye acetato de ciproterona, drospirenona, espironolactona, flutamida y finasterida. El síndrome por exceso de eliminación de andrógenos ováricos (SAHA ovárico) y alopecia del hiperandrogenismo ovárico pueden tratarse con supresión ovárica y andriandrógenos. La supresión ovárica incluye el uso de anticonceptivos que contengan un estrógeno, etinilestradiol, y un progestágeno. El antiandrógeno acetato de ciproterona, siempre acompañado de un anticonceptivo tricíclico, es la mejor terapéutica de la alopecia femenina. Los antagonistas de las hormonas liberadoras de gonadotropinas (GnRH) como el acetato de leuprolida suprimen la función hipofisaria y gonadal mediante la reducción de los niveles de LH y FSH, y como consecuencia se reducen los niveles de esteroides ováricos, especialmente en el síndrome de los ovarios poliquísticos. El SAHA hiperprolactinémico y alopecia del hiperandrogenismo de procedencia hipofisaria deben tratarse con bromocriptina o cabergolina. Las mujeres con alopecia posmenopáusica y altos niveles séricos de andrógenos en la premenopausia...


Topical treatment of female patgten hair loss (FPHL) is with minoxidil 3 percent-5 percent twice daily. Combination of minoxidil with α-tocopherol or with other topical treatment with possibility to enhance VEGF can be used. Our experience with this association is commented. Side effect of minoxidil is contact dermatitis and hipertricosis on face and forearm. When FPHL is associated with high levels of androgens systemic antiandrogenic therapy must be used. Persistent adrenarche syndrome (adrenal SAHA) and alopecia of adrenal hiperandrogenism must be treated with adrenal suppression and antiandrogens. Adrenal suppression is achieved with glucocorticosteroids such as dexametasona, prednisone ordeflazacort. Antiandrogen therapy includes cyproterone acetate, drospirenone, spironolactone, flutamide and finasteride. Excess release of ovarian androgens (ovarian SAHA) and alopecia of ovarian hiperandrogenism must be treated with ovarian suppression and antiandrogens. Ovarian suppression includes the use of contraceptives containing an estrogen, ethinyl estradiol, and a progestogen. Antiandrogens such as cyproterone acetate, always accompanied by tricyclic contraceptives, are the best antiandrogen to use in FPHL. Gonadotropin-releasing hormone (GnRH) agonists such as leuprolide acetate suppress pituitary and gonadal function through a reduction in LH andFSH levels. Subsequently, ovarian steroids levels will also be reduced, especially in patients with polycystic ovary syndrome. SAHA with hyperprolactinemia and alopecia of hyperprolactinemic hiperandrogenism should be treated with bromocriptineor cabergoline. Postmenopausal alopecia, with previous high levels of androgens or with PSA over 0.02 ng/ml improves with 2.5 mg/day of finasteride or 0,25 mg/day of Dutasteride. Although we do not know the reason, postmenopausal alopecia in normoandrogenic women also improves, probably in relation with the doses of 2.5 mg day that received...


Subject(s)
Humans , Female , Administration, Topical , Alopecia/drug therapy , Azasteroids/administration & dosage , Finasteride/administration & dosage , Minoxidil/administration & dosage , Cosmetic Techniques , Adrenal Glands
17.
Arq. bras. oftalmol ; 74(1): 55-57, Jan.-Feb. 2011. ilus, tab
Article in English | LILACS | ID: lil-589941

ABSTRACT

Ichthyosis follicular, alopecia, and photophobia (IFAP) syndrome is a rare disease, with possible X-linked mode of inheritance. The patient presented with ocular findings of photophobia, corneal scarring and erosions, superficial and deep corneal vascularization and myopia. He was treated with artificial tears and punctal occlusion with small improvement of photophobia. After three months using systemic retinoid (Acitretina) and posterior amniotic membrane transplantation in the left eye, there was a significant improvement of photophobia, corneal erosions and neuropsychomotor development.


A síndrome de ictiose folicular, alopecia e fotofobia (IFAP) é uma doença rara, com possível modo de herança ligado ao cromossomo X. O paciente apresentou achados oftalmológicos de fotofobia, cicatrizes e erosão corneanas, neovascularização superficial e profunda da córnea e miopia. Foi iniciado uso de lubrificantes e oclusão do ponto lacrimal com discreta melhora da fotofobia. Após uso de retinóide sistêmico (Acitretina) por três meses e posterior transplante de membrana amniótica no olho esquerdo apresentou melhora importante da fotofobia, das erosões corneanas e do desenvolvimento neuropsicomotor.


Subject(s)
Child, Preschool , Humans , Male , Alopecia/diagnosis , Ichthyosis/diagnosis , Photophobia/diagnosis , Acitretin/therapeutic use , Alopecia/drug therapy , Amnion/transplantation , Ichthyosis/drug therapy , Keratolytic Agents/therapeutic use , Photophobia/surgery , Syndrome
19.
Rev. chil. dermatol ; 25(1): 21-25, 2009. tab, graf
Article in Spanish | LILACS | ID: lil-525459

ABSTRACT

Introducción: La calvicie más común es la alopecia androgenética, la cual consiste en una pérdida progresiva del cabello inducida por la acción de los andrógenos a nivel del folículo piloso. Objetivos: Evaluar la utilidad y seguridad del 17-alfa-estradiol al 0,025 por ciento en el tratamiento de la alopecia androgenética. Material y Métodos: Uso de una solución tópica capilar de 17-alfa-estradiol al 0,025 por ciento versus minoxidil al 2 por ciento en solución tópica capilar, durante 12 semanas, en pacientes chilenos con diagnóstico de alopecia androgenética mediante el análisis cuantitativo del videotricograma. Resultados: Se observó una tendencia al aumento de los cabellos en anágeno y disminución de los cabellos en telógeno en los pacientes tratados con 17-alfa-estradiol al 0,025 por ciento en la zona frontoparietal sin aparición de efectos adversos.


Introduction: Androgenetic alopecia is the most common cause of baldness. It consists of progressive hair loss induced by the action of androgens in the hair follicle. Aim: To evaluate usefulness and safety of 0.025 percent 17-alpha-estradiol in the treatment of androgenetic alopecia. Material and Methods: Use of a topic hair solution of 0.025 percent 17-alpha-estradiol versus 2 percent minoxidil topic hair solution for twelve weeks in Chilean patients with clinically diagnosed androgenetic alopecia through quantitative analysis with videotrichogram. Results: Patients treated with 0.025 percent 17-alpha-estradiol showed a tendency to increase the number of hair follicles in anagen phase and a decrease in telogen phase in the frontoparietal zone with no adverse events.


Subject(s)
Humans , Male , Adult , Female , Middle Aged , Alopecia/drug therapy , Estradiol/therapeutic use , Minoxidil/therapeutic use , Administration, Topical , Alopecia/pathology , Hair/growth & development , Hair , Chile/epidemiology , Double-Blind Method , Estradiol/pharmacology , Microscopy, Video , Minoxidil/pharmacology , Patient Satisfaction , Severity of Illness Index , Treatment Outcome
20.
Arq. bras. endocrinol. metab ; 52(8): 1244-1251, Nov. 2008. ilus, graf, tab
Article in English | LILACS | ID: lil-503289

ABSTRACT

Mutations in the vitamin D receptor (VDR) are associated to the hereditary 1,25-dihydroxivitamin D-resistant rickets. The objectives of this work are: search for mutations in the VDR and analyze their functional consequences in four Brazilian children presented with rickets and alopecia. The coding region of the VDR was amplified by PCR e direct sequenced. We identified three mutations: two patients had the same mutation in exon 7 at aminoacid position 259 (p.Q259E); one patient had a mutation in exon 8 at codon 319 (p.G319V) and another one had a mutation in exon 3 leading to a truncated protein at position 73 (p.R73X). Functional studies of the mutant receptors of fibroblast primary culture, from patients' skin biopsy treated with increasing doses of 1,25(OH)2 vitamin D showed that VDR mutants were unable to be properly activated and presented a reduction in 24-hydroxylase expression level.


Mutações no receptor de vitamina D (VDR) são associadas a raquitismo hereditário resistente a 1,25-dihidroxivitamina D. Os objetivos deste trabalho foram procurar mutações no VDR e analisar suas conseqüências funcionais em quatro pacientes com raquitismo e alopécia. A região codificadora do VDR foi amplificada por PCR e seqüenciada diretamente. Identificamos três mutações: dois pacientes apresentavam a mesma mutação no éxon 7 na posição protéica 259 (p.Q259E); um paciente apresentava uma mutação no éxon 8 no códon 319 (p.G319V) e o outro apresentava uma mutação no exon 3 resultando em uma proteína truncada na posição 73 (p.R73X). O estudo funcional dos receptores mutados nos extratos de culturas de fibroblasto primárias obtidas de biópsia de pele dos pacientes, tratados com doses crescentes de 1,25(OH)2 vitamina D demonstraram que os receptores mutantes não apresentam ativação adequada apresentando expressão reduzida de 24-hidroxilase.


Subject(s)
Child , Female , Humans , Male , Young Adult , Alopecia/genetics , Familial Hypophosphatemic Rickets/genetics , Mutation , Receptors, Calcitriol/genetics , Alopecia/drug therapy , Base Sequence , Calcitriol/therapeutic use , Fibroblasts/drug effects , Fibroblasts/enzymology , Familial Hypophosphatemic Rickets/drug therapy , RNA, Messenger/genetics , RNA, Messenger/metabolism , Receptors, Calcitriol/metabolism , Sequence Analysis, DNA , Steroid Hydroxylases/genetics , Steroid Hydroxylases/metabolism , Vitamins/therapeutic use , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL